A Randomized Phase 2, Open-Label Study Of CP-751,871 [CP 751871] In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Docetaxel (Primary) ; Figitumumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 03 Dec 2008 Planned end date changed from 1 May 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 03 Dec 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.